Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study

Basit Öğe Kaydı
dc.authoridçakır, emre/0000-0003-0411-8818
dc.authoridFerhatoglu, Ferhat/0000-0002-7651-6789
dc.authoridPaksoy, Nail/0000-0003-4636-2595
dc.authoridAk, Naziye/0000-0001-5790-7066
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridayhan, murat/0000-0002-0631-4006
dc.authoridCil, Ibrahim/0000-0002-6388-0346
dc.authorwosidAvcı, Okan/ABG-8782-2021
dc.authorwosidAy, Murat/GSI-4353-2022
dc.authorwosidçakır, emre/JVZ-2045-2024
dc.authorwosidFerhatoglu, Ferhat/AAT-5977-2021
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidmustafa, Muhammed/HME-1300-2023
dc.authorwosidÖnder, Arif Hakan/JBI-7691-2023
dc.contributor.authorCil, Ibrahim
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorAtci, Muhammed Mustafa
dc.contributor.authorSecmeler, Saban
dc.contributor.authorPaksoy, Nail
dc.contributor.authorFerhatoglu, Ferhat
dc.contributor.authorAk, Naziye
dc.date.accessioned2024-06-12T11:03:10Z
dc.date.available2024-06-12T11:03:10Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate and its survival advantage has been shown in advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, clinical trials underrepresent patients > 65 years of age, leading to a lack of information in this population. We analyzed the real-world outcomes of older women who were treated with T-DM1 therapy. Methods: We performed a multicenter, observational, retrospective analysis of patients aged > 65 years treated with T-DM1. A total of 93 patients from 10 cancer centers were involved in the study. Our goal was to determine the survival, response rates, and toxicity profile in T-DM1-treated patients, as well as the factors that influence survival. Results: Median follow-up was 12.2 months. Objective response rate was 29%. Median progression-free survival (PFS) and overall survival (OS) were 8.47 and 15.0 months, respectively. In multivariate analysis, Eastern Cooperative Oncology Group Performance Score 2 was found to be an independent prognostic factor for worse PFS (hazard ratio [HR] 1.81, p = 0.032) and OS (HR 2.33, p = 0.006). Any adverse event (AE) was seen in 92.5% of patients; grade 3 or 4 AEs were seen in 30.1%. Dose reduction or treatment discontinuation rates were 11.8% and 6.5%, respectively. Conclusion: The efficacy of T-DM1 was acceptable and it was generally well-tolerated among older patients with advanced HER2-positive breast cancer.en_US
dc.identifier.doi10.1177/03008916211037739
dc.identifier.endpage25en_US
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue1en_US
dc.identifier.pmid34365852en_US
dc.identifier.scopus2-s2.0-85112296856en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage19en_US
dc.identifier.urihttps://doi.org/10.1177/03008916211037739
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21557
dc.identifier.volume108en_US
dc.identifier.wosWOS:000685650500001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumori Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHER2 Positiveen_US
dc.subjectMetastatic Breast Canceren_US
dc.subjectOlder Patientsen_US
dc.subjectReal-Worlden_US
dc.subjectPhysiological-Aspectsen_US
dc.subjectDecision-Makingen_US
dc.subjectAgeen_US
dc.subjectManagementen_US
dc.subjectSurvivalen_US
dc.subjectImpacten_US
dc.subjectT-Dm1en_US
dc.subjectWomenen_US
dc.titleEfficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu